David Bishop-Bailey

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi PPAR receptor activation: Experimental studies on cardiac structure and function
    David Bishop-Bailey
    Queen Mary University of London, Translational Medicine and Therapeutics, William Harvey Research Institute, Charterhouse Square, London, EC1M6BQ, UK
    Curr Opin Investig Drugs 11:283-8. 2010
  2. pmc The Role of PPARs in the Endothelium: Implications for Cancer Therapy
    David Bishop-Bailey
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK
    PPAR Res 2008:904251. 2008
  3. pmc A Role for PPARbeta/delta in Ocular Angiogenesis
    David Bishop-Bailey
    Centre of Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    PPAR Res 2008:825970. 2008
  4. doi PPARs and angiogenesis
    David Bishop-Bailey
    William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Biochem Soc Trans 39:1601-5. 2011
  5. ncbi FXR as a novel therapeutic target for vascular disease
    David Bishop-Bailey
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University London, London, UK
    Drug News Perspect 17:499-504. 2004
  6. doi Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation
    David Bishop-Bailey
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Pharmacol Ther 124:141-50. 2009
  7. doi The platelet as a model system for the acute actions of nuclear receptors
    David Bishop-Bailey
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1 M 6BQ, UK
    Steroids 75:570-5. 2010
  8. pmc Expression and activation of the farnesoid X receptor in the vasculature
    David Bishop-Bailey
    Cardiac, Vascular, and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
    Proc Natl Acad Sci U S A 101:3668-73. 2004
  9. ncbi PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist
    David Bishop-Bailey
    Department of Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    FASEB J 17:1925-7. 2003
  10. ncbi Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation
    David Bishop-Bailey
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts, UK
    Prostaglandins Other Lipid Mediat 71:1-22. 2003

Collaborators

Detail Information

Publications39

  1. ncbi PPAR receptor activation: Experimental studies on cardiac structure and function
    David Bishop-Bailey
    Queen Mary University of London, Translational Medicine and Therapeutics, William Harvey Research Institute, Charterhouse Square, London, EC1M6BQ, UK
    Curr Opin Investig Drugs 11:283-8. 2010
    ..This review discusses the evidence for the functions of PPARs as well as the new and emerging roles of PPAR pathways in cardiac structure and function...
  2. pmc The Role of PPARs in the Endothelium: Implications for Cancer Therapy
    David Bishop-Bailey
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK
    PPAR Res 2008:904251. 2008
    ..In particular, we will discuss the recent evidence that supports the hypothesis that PPARalpha and PPARgamma are antiangiogenic receptors, while PPARbeta/delta is proangiogenic...
  3. pmc A Role for PPARbeta/delta in Ocular Angiogenesis
    David Bishop-Bailey
    Centre of Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    PPAR Res 2008:825970. 2008
    ..This review, therefore, will discuss the recent evidence of PPARbeta/delta-mediated angiogenesis and VEGF release in the context of ocular disorders...
  4. doi PPARs and angiogenesis
    David Bishop-Bailey
    William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Biochem Soc Trans 39:1601-5. 2011
    ..This evidence and the emerging mechanisms by which PPARs act in endothelial cells are discussed in more detail...
  5. ncbi FXR as a novel therapeutic target for vascular disease
    David Bishop-Bailey
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University London, London, UK
    Drug News Perspect 17:499-504. 2004
    ..This review aims to introduce the FXR literature and discuss the mechanisms by which FXR may both directly and indirectly affect the progression of cardiovascular disease...
  6. doi Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation
    David Bishop-Bailey
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Pharmacol Ther 124:141-50. 2009
    ..In contrast, the roles of PPARbeta/delta regulating inflammation and immunity are only just emerging. This review will focus on these emerging roles of PPARbeta/delta in regulating inflammatory processes...
  7. doi The platelet as a model system for the acute actions of nuclear receptors
    David Bishop-Bailey
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1 M 6BQ, UK
    Steroids 75:570-5. 2010
    ....
  8. pmc Expression and activation of the farnesoid X receptor in the vasculature
    David Bishop-Bailey
    Cardiac, Vascular, and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
    Proc Natl Acad Sci U S A 101:3668-73. 2004
    ..FXR therefore is a functional protein in the vasculature that may provide a direct target for the treatment of proliferative and dyslipidaemic diseases...
  9. ncbi PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist
    David Bishop-Bailey
    Department of Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    FASEB J 17:1925-7. 2003
    ..In contrast, indomethacin, an alternative inhibitor of cyclooxygenase activity, inhibited both rosiglitazone-induced cell death, and rosiglitazone-induced PPAR reporter gene activation...
  10. ncbi Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation
    David Bishop-Bailey
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts, UK
    Prostaglandins Other Lipid Mediat 71:1-22. 2003
    ..Using classical pharmacological criteria for endogenous mediator classification we will critically discuss the variety of pathways for putative ligand generation...
  11. ncbi Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy
    David Bishop-Bailey
    Department of Cardiac, Vascular, and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University of London, London, UK
    Circ Res 91:210-7. 2002
    ..Intimal vascular smooth muscle cells therefore represent a potentially important target for the antiproliferative, and antiatherosclerotic actions of PPARgamma ligands...
  12. doi Tumour vascularisation: a druggable target
    David Bishop-Bailey
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, United Kingdom
    Curr Opin Pharmacol 9:96-101. 2009
    ....
  13. pmc Endogenous epoxygenases are modulators of monocyte/macrophage activity
    Jonas Bystrom
    William Harvey Research Institute, Queen Mary University London, London, United Kingdom
    PLoS ONE 6:e26591. 2011
    ..Unlike cyclooxygenase and lipoxygenases, the role of CYP450 epoxygenases in monocyte/macrophage-mediated responses is not known...
  14. ncbi Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration
    Yoyo T Y Li
    Centre of Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, United Kingdom
    Arterioscler Thromb Vasc Biol 27:2606-11. 2007
    ..FXR is also expressed in vascular tissue. We have investigated whether FXR regulates inflammation and migration in vascular smooth muscle cells...
  15. ncbi Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta
    Ferhana Y Ali
    Unit of Critical Care Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    FASEB J 20:326-8. 2006
    ..Thus, our results identify PPARbeta as a novel antiplatelet target that may mediate some of the effects of prostacyclin in blood...
  16. pmc The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo
    Jessica A Wray
    Translational Medicine and Therapeutics, William Harvey Research Institute, London, United Kingdom
    PLoS ONE 4:e7421. 2009
    ..However, little is known regarding the endogenous generation of PPAR ligands. CYP2J2 is a lipid metabolising cytochrome P450, which produces anti-inflammatory mediators, and is considered the major epoxygenase in the human heart...
  17. ncbi The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression
    Karen E Swales
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Charterhouse Square, London EC1M 6BQ, United Kingdom
    Cancer Res 66:10120-6. 2006
    ..Our findings show for the first time that FXR is expressed in breast cancer tissue and has multiple properties that could be used for the treatment of breast cancer...
  18. ncbi Prostaglandins and the regulation of tumor growth
    David Bishop-Bailey
    Department of Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Queen Mary s University, London, UK
    J Environ Pathol Toxicol Oncol 21:93-101. 2002
    ..Effecting individual prostanoid pathways at the level of COX expression, profile of PG products produced or selective PG receptor activation may produce novel therapies, either dependent or independent of CSF release, to target cancers...
  19. ncbi Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis
    Laura Piqueras
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University London, Charterhouse Sq, London EC1M 6BQ, UK
    Arterioscler Thromb Vasc Biol 27:63-9. 2007
    ..Interestingly, the selective PPARbeta/delta ligand GW501516 is in phase II clinical trials for dyslipidemia. Here, using GW501516, we have assessed the involvement of PPARbeta/delta in endothelial cell proliferation and angiogenesis...
  20. ncbi Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy
    Hema J Patel
    Respiratory Pharmacology Group, Department of Cardiothoracic Surgery, Faculty of Medicine, The National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
    J Immunol 170:2663-9. 2003
    ..Hence, PPAR ligands might act as potential treatments in human respiratory diseases...
  21. pmc Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets
    Leonardo A Moraes
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London, UK
    Blood 109:3741-4. 2007
    ..Furthermore, our results demonstrate a novel nongenomic mode for nuclear receptor action and a functional cross-talk between G-protein and nuclear receptor signaling families...
  22. doi PPARα-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status
    Paul W Caton
    Centre for Diabetes, Blizard Institute, Bart s and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, UK
    Biochem J 437:521-30. 2011
    ..In summary, we therefore propose that a LXR-PPARα signalling axis acts as a metabolostatic regulatory mechanism to optimize substrate selection and disposition in skeletal muscle according to metabolic requirement...
  23. ncbi Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues
    Timothy D Warner
    William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London, United Kingdom
    J Pharmacol Exp Ther 310:642-7. 2004
    ..Also, our experiments show that the ability of rofecoxib to depress the circulating levels of prostaglandin I(2) is more readily associated with its ability to reduce production from the lung, heart, or brain than from arterial vessels...
  24. ncbi Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts
    Ferhana Y Ali
    Cardiothoracic Pharmacology, Unit of Critical Care Medicine, National Heart and Lung Institute, Imperial College, London, UK
    Am J Respir Cell Mol Biol 34:242-6. 2006
    ..This study is the first to identify PPARbeta as a potential therapeutic target for the treatment of pulmonary hypertension, which is important because orally active PPARbeta ligands have been developed for the treatment of dyslipidemia...
  25. ncbi Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2
    Timothy D Warner
    The William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London, UK
    FASEB J 20:542-4. 2006
    ..In particular, selectivity in one body compartment does not demonstrate selectivity in another. Thus, whole-body safety or toxicity cannot be linked to one definitive measure of COX selectivity...
  26. ncbi Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology
    Jessica Wray
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK
    Exp Physiol 93:148-54. 2008
    ..The epoxygenase-EET-PPAR pathway may therefore represent a novel endogenous protective pathway by which short-lived lipid mediators control vascular cell activation...
  27. pmc Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease?
    Jonas Bystrom
    William Harvey Research Institute, Queen Mary University, London, United Kingdom
    PLoS ONE 8:e75107. 2013
    ..coli. These results demonstrate that CYP2J2 mediates bacterial phagocytosis in macrophages, and implicates a defect in the CYP2J2 pathway may regulate bacterial clearance in Crohn's disease. ..
  28. pmc Roles of the epoxygenase CYP2J2 in the endothelium
    Ara Askari
    Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
    Prostaglandins Other Lipid Mediat 107:56-63. 2013
    ..This review will examine these established and emerging roles of CYP2J2 in the biology of vascular endothelial cells. ..
  29. ncbi Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells
    Mandy Woods
    Department of Cardiac, Vascular and Inflammation Research, The William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK
    Mol Pharmacol 64:923-31. 2003
    ....
  30. pmc Basal and inducible anti-inflammatory epoxygenase activity in endothelial cells
    Ara A Askari
    Barts and The London, Queen Mary University, London, UK
    Biochem Biophys Res Commun 446:633-7. 2014
    ..In conclusion, human endothelial cells contain a TLR-4 regulated epoxygenase CYP2J2 and metabolize linoleic acid>eicosapentaenoic acid > arachidonic acid>docosahexaenoic acid to products with anti-inflammatory activity...
  31. doi Dissecting the role of eosinophil cationic protein in upper airway disease
    Jonas Bystrom
    Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary University of London, London, UK
    Curr Opin Allergy Clin Immunol 12:18-23. 2012
    ..The contribution of eosinophils and their granule proteins to disease pathogenesis have been debated; recent findings might bring these cells to the center of attention...
  32. doi Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock
    Amar Kapoor
    Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, London, United Kingdom
    Am J Respir Crit Care Med 182:1506-15. 2010
    ..Peroxisome proliferator-activated receptor (PPAR)-β/δ is a transcription factor that belongs to the PPAR nuclear hormone receptor family, but the role of PPAR-β/δ in sepsis is unknown...
  33. pmc Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation
    Nicholas S Kirkby
    National Heart and Lung Institute, Imperial College London, London, United Kingdom William Harvey Research Institute, Queen Mary University of London, London, United Kingdom National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
    FASEB J 29:4568-78. 2015
    ..8% of control) were similar to healthy volunteer levels. These studies constitute a definitive account, demonstrating the fundamental role of cPLA2α to eicosanoid formation and cellular responses within the human circulation...
  34. ncbi COX-2 in cardiovascular disease
    David Bishop-Bailey
    Arterioscler Thromb Vasc Biol 26:956-8. 2006
  35. ncbi Peroxisome proliferator-activated receptors and inflammation
    Leonardo A Moraes
    Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Pharmacol Ther 110:371-85. 2006
    ..Furthermore, PPAR levels are differentially regulated in a variety of inflammatory disorders in man, where ligands appear to be promising new therapies...
  36. pmc Analysing the eosinophil cationic protein--a clue to the function of the eosinophil granulocyte
    Jonas Bystrom
    Translational Medicine and Therapeutics, William Harvey Research Institute, Bart s and The London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Respir Res 12:10. 2011
    ....
  37. pmc A thin layer angiogenesis assay: a modified basement matrix assay for assessment of endothelial cell differentiation
    Ashton Faulkner
    Comparative Biomedical Sciences, Royal Veterinary College, University of London Royal College Street, London, NW1 0TU, UK
    BMC Cell Biol 15:41. 2014
    ..Here we describe the development and validation of a thin-layer angiogenesis (TLA) assay for assessing the angiogenic potential of endothelial cells that overcomes these limitations...
  38. doi The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas
    Chrysanthia A Leontiou
    Department of Endocrinology, Barts and the London School of Medicine, London, United Kingdom
    J Clin Endocrinol Metab 93:2390-401. 2008
    ..Mutations have been identified in the aryl hydrocarbon receptor-interacting protein (AIP) gene in familial isolated pituitary adenomas (FIPA). It is not clear, however, how this molecular chaperone is involved in tumorigenesis...
  39. doi Peroxisome proliferator-activated receptor beta/delta goes vascular
    David Bishop-Bailey
    Circ Res 102:146-7. 2008